Streptococcus pneumoniae serotype 19F (S. pneumoniae 19F)

Streptococcus pneumoniae serotype 19F is a Gram-positive encapsulated bacterium classified within the species S. pneumoniae based on its unique capsular polysaccharide structure ("serotype"). The capsule is a major virulence factor that enables evasion from host immune responses by resisting opsonophagocytosis and complement deposition—serotype 19F strains are notably more resistant than some other types like 6B[1]. Serotype 19F is one of the most prevalent causes of invasive pneumococcal diseases worldwide—including community-acquired pneumonia, meningitis, otitis media, and sepsis—especially among children under five years old. This serotype exhibits high rates of antimicrobial resistance—including penicillin non-susceptibility and multidrug resistance—largely mediated by acquired genes such as erm(B) for macrolide resistance and tet(M) for tetracycline resistance. The genetic diversity within this group includes sequence types like ST271 that are associated with both high virulence and drug resistance profiles[3][4]. Serotyping relies on detection of specific capsular biosynthesis genes such as wzy; however, allelic variants can lead to misclassification between closely related types like 19A/19F. Serotype-specific antigens from S. pneumoniae including those from type 19F form key components in current conjugate vaccines (such as PCV13). However, ongoing evolution may impact vaccine coverage effectiveness over time due to emerging variants not covered by existing formulations or changes in local epidemiology.[6][8]

Other names

Pneumococcus serotype 19FS. pneumoniae type 19FStreptococcus pneumoniae type 19F

Drugs act by inhibiting bacterial cell wall synthesis (beta-lactams), protein synthesis (macrolides, tetracyclines), or DNA replication; however, resistance genes such as erm(B) and tet(M) are common in this serotype, reducing drug efficacy[4].